Shots:

• Health Canada has approved Ziextenzo (a biosimilar referencing Neulasta) and Riximyo (a biosimilar referencing Rituxan) for marketing in Canada
• Sandoz has received Health Canada’s Notice of Compliance on Apr 21- 2020- for the use of Ziextenzo to reduce the incidence of febrile neutropenia while Riximyo has received approval on Apr 28- 2020 to treat NHL- CLL and RA
• The approval of Ziextenzo and Riximyo expands Sandoz’s oncology biosimilar portfolio. The approval reinforces Sandoz’ status as the leading biosimilar and generic pharmaceutical company in Canada

Click here to read full press release/ article | Ref: BuinessWire | Image: Twitter